Publications by authors named "Elisabetta Cartechini"

Claim this Profile
M
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Elisabetta Cartechini

Mult Scler· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.
Enrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, Carlos Moreno-Bernardino, Graciela Elizabeth De la Mora-Landín, Elisabetta Cartechini

Ther Adv Neurol Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Elisabetta Cartechini

J Neurol Neurosurg Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent progression independent of relapse activity in multiple sclerosis.
Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Elisabetta Cartechini

Brain Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.
Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Elisabetta Cartechini

NPJ Digit Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Elisabetta Cartechini

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Dana Horakova, Eva Kubala Havrdova, Elisabetta Cartechini

CNS Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G Chisari, Elisabetta Cartechini

Neurotherapeutics· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Wei Z Yeh, Anneke Van Der Walt, Olga G Skibina, Tomas Kalincik, Raed Alroughani, Elisabetta Cartechini

Neurol Neuroimmunol Neuroinflamm· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
David Levitz, Yi Chao Foong, Paul Sanfilippo, Tim Spelman, Louise Rath, Elisabetta Cartechini

Ther Adv Neurol Disord· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
Cathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, Vincent Van Pesch, Francesco Patti, Elisabetta Cartechini

J Neurol Neurosurg Psychiatry· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
Edward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, Pieter Dewulf, Dimitrios Iliadis, Elisabetta Cartechini

PLOS Digit Health· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Ibrahima Diouf, Charles B Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Elisabetta Cartechini

J Neurol Neurosurg Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of secondary progressive multiple sclerosis after early worsening of disability.
Winston Dzau, Sifat Sharmin, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Elisabetta Cartechini

J Neurol Neurosurg Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability accrual in primary and secondary progressive multiple sclerosis.
Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B Malpas, Ibrahima Diouf, Elisabetta Cartechini

J Neurol Neurosurg Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Elisabetta Cartechini

JAMA Neurol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Ibrahima Diouf, Charles B Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Elisabetta Cartechini

Eur J Neurol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Elisabetta Cartechini

Mult Scler· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Tomas Kalincik, Ilya Kister, Tamar E Bacon, Charles B Malpas, Sifat Sharmin, Elisabetta Cartechini

Mult Scler· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Izanne Roos, Charles Malpas, Emmanuelle Leray, Romain Casey, Dana Horakova, Elisabetta Cartechini

Neurology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Sifat Sharmin, Francesca Bovis, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Elisabetta Cartechini

Eur J Neurol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Elisabetta Cartechini

Neurology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].
Edward De Brouwer, Thijs Becker, Yves Moreau, Eva Kubala Havrdova, Maria Trojano, Elisabetta Cartechini

Comput Methods Programs Biomed· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry.
Rachel Kenney, Mengling Liu, Sachi Patil, Raed Alroughani, Radek Ampapa, Elisabetta Cartechini

J Neurol Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression.
Edward De Brouwer, Thijs Becker, Yves Moreau, Eva Kubala Havrdova, Maria Trojano, Elisabetta Cartechini

Comput Methods Programs Biomed· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis